Open Access

A novel resveratrol analog PA19 attenuates obesity‑induced cardiac and renal injury by inhibiting inflammation and inflammatory cell infiltration

  • Authors:
    • Wenxin Zhang
    • Hongjin Chen
    • Chuchu Sun
    • Beibei Wu
    • Bin Bai
    • Hui Liu
    • Xiaoou Shan
    • Guang Liang
    • Yali Zhang
  • View Affiliations

  • Published online on: April 12, 2019     https://doi.org/10.3892/mmr.2019.10157
  • Pages: 4770-4778
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Obesity is a major global health concern and induces numerous complications, such as heart and kidney injury. Inflammation is an important pathogenic mechanism underlying obesity‑associated tissue injury. (1E,4E)‑1‑{2,4‑Dimethoxy‑6‑[(E)‑4‑methoxystyryl]phenyl}‑5‑​(2,4‑dimethoxyphenyl)penta‑1,4‑dien‑3‑one (PA19) is a novel anti‑inflammatory compound synthesized by our research group. In the present study, the efficacy of PA19 in attenuating high‑fat diet (HFD)‑induced heart and kidney injury was investigated. Heart and kidney pathological injury and fibrosis were detected by hematoxylin and eosin and Sirius red staining, respectively. The expression levels of inflammatory genes and fibrosis‑associated protein were determined by reverse transcription‑quantitative polymerase chain reaction and western blotting. ELISA was used to detect the level of inflammatory cytokines. Following 20 weeks of HFD treatment, mice exhibited increased lipid accumulation in the serum, heart and kidney injury and fibrosis, and inflammation and inflammatory cell infiltration compared with mice fed a control diet. Conversely, treatment with PA19 during the final 12 weeks of the study significantly reduced the degree of heart and kidney fibrosis and inflammation induced by HFD. The results suggested that PA19 attenuates heart and kidney inflammation and injury induced by HFD, and indicated that PA19 may be a novel therapeutic agent in the treatment of obesity, and obesity‑induced cardiac and renal injury.

References

1 

Long JR, Shu XQ, Cai Q, Wen W, Kataoka N, Gao YT and Zheng W: CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women. Int J Obes (Lond). 31:418–423. 2007. View Article : Google Scholar : PubMed/NCBI

2 

Polyzos SA, Kountouras J and Mantzoros CS: Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol. 42:92–108. 2017.PubMed/NCBI

3 

Roberts CK, Hevener AL and Barnard RJ: Metabolic syndrome and insulin resistance: Underlying causes and modification by exercise training. Compr Physiol. 3:1–58. 2013.PubMed/NCBI

4 

Turer CB, Brady TM and de Ferranti SD: Obesity, hypertension, and dyslipidemia in childhood are key modifiable antecedents of adult cardiovascular disease: A call to action. Circulation. 137:1256–1259. 2018. View Article : Google Scholar : PubMed/NCBI

5 

Abderrahmani A, Yengo L, Caiazzo R, Canouil M, Cauchi S, Raverdy V, Plaisance V, Pawlowski V, Lobbens S, Maillet J, et al: Increased hepatic PDGF-AA signaling mediates liver insulin resistance in obesity associated type 2 diabetes. Diabetes. 67:1310–1321. 2018. View Article : Google Scholar : PubMed/NCBI

6 

Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB and Vasan RS: Obesity and the risk of heart failure. N Engl J Med. 347:305–313. 2002. View Article : Google Scholar : PubMed/NCBI

7 

Wahba IM and Mak RH: Obesity and obesity-initiated metabolic syndrome: Mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2:550–562. 2007. View Article : Google Scholar : PubMed/NCBI

8 

de Heredia FP, Gómez-Martínez S and Marcos A: Obesity, inflammation and the immune system. Proc Nutr Soc. 71:332–338. 2012. View Article : Google Scholar : PubMed/NCBI

9 

Cancello R and Clement K: Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG. 113:1141–1147. 2006. View Article : Google Scholar : PubMed/NCBI

10 

Graziani F, Cialdella P, Liuzzo G, Basile E, Brugaletta S, Pedicino D, Leccesi L, Guidone C, Iaconelli A, Mingrone G, et al: Cardiovascular risk in obesity: Different activation of inflammation and immune system between obese and morbidly obese subjects. Eur J Intern Med. 22:418–423. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Vors C, Couillard C, Paradis M, Gigleux I, Marin J, Vohl M, Couture P and Lamarche B: Supplementation with resveratrol and curcumin does not affect the inflammatory response to a high-fat meal in older adults with abdominal obesity: A randomized, placebo-controlled crossover trial. J Nutr. 148:379–388. 2018. View Article : Google Scholar : PubMed/NCBI

12 

Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, Oh GT, Park HS, Lee KU, Lane MD and Kim JB: Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab. 296:E812–E819. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Rossi EL, Khatib SA, Doerstling SS, Bowers LW, Pruski M, Ford NA, Glickman RD, Niu M, Yang P, Cui Z, et al: Resveratrol inhibits obesity-associated adipose tissue dysfunction and tumor growth in a mouse model of postmenopausal claudin-low breast cancer. Mol Carcinog. 57:393–407. 2018. View Article : Google Scholar : PubMed/NCBI

14 

Pan J, Xu T, Xu F, Zhang Y, Liu Z, Chen W, Fu W, Dai Y, Zhao Y, Feng J and Liang G: Development of resveratrol-curcumin hybrids as potential therapeutic agents for inflammatory lung diseases. Eur J Med Chem. 125:478–491. 2017. View Article : Google Scholar : PubMed/NCBI

15 

Zong Y, Sun L, Liu B, Deng YS, Zhan D, Chen YL, He Y, Liu J, Zhang ZJ, Sun J and Lu D: Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine RAW 264.7 macrophage cells. PLoS One. 7:e441072012. View Article : Google Scholar : PubMed/NCBI

16 

Lee SM, Zhang Y, Tsuchiya H, Smalling R, Jetten AM and Wang L: Small heterodimer partner/neuronal PAS domain protein 2 axis regulates the oscillation of liver lipid metabolism. Hepatology. 61:497–505. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

18 

Latifi SM, Karandish M, Shahbazian H, Taha JM, Cheraghian B and Moradi M: Prevalence of Metabolically Healthy Obesity (MHO) and its relation with incidence of metabolic syndrome, hypertension and type 2 diabetes amongst individuals aged over 20 years in Ahvaz: A 5 year cohort study (2009–2014). Diabetes Metab Syndr. 11 (Suppl 2):S1037–S1040. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Siddeek B, Li N, Mauduit C, Chehade H, Rigal E, Tolsa J, Armengaud J, Yzydorczyk C, Benahmed M, Vergely C and Simeoni U: Transient postnatal over nutrition induces long-term alterations in cardiac NLRP3-inflammasome pathway. Nutr Metab Cardiovasc Dis. 28:944–951. 2018. View Article : Google Scholar : PubMed/NCBI

20 

Blokhin IO and Lentz SR: Mechanisms of thrombosis in obesity. Curr Opin Hematol. 20:437–444. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Köchli S, Endes K, Infanger D, Zahner L and Hanssen H: Obesity, blood pressure, and retinal vessels: A meta-analysis. Pediatrics. 141:e201740902018. View Article : Google Scholar : PubMed/NCBI

22 

Davis S, Nehus E, Inge T, Zhang W, Setchell K and Mitsnefes M: Effect of bariatric surgery on urinary sphingolipids in adolescents with severe obesity. Surg Obes Relat Dis. 14:446–451. 2018. View Article : Google Scholar : PubMed/NCBI

23 

Hall JE, Henegar JR, Dwyer TM, Liu J, Da Silva AA, Kuo J and Tallam L: Is obesity a major cause of chronic kidney disease? Adv Ren Replace Ther. 11:41–54. 2004. View Article : Google Scholar : PubMed/NCBI

24 

Sowers JR: Metabolic risk factors and renal disease. Kidney Int. 71:719–720. 2007. View Article : Google Scholar : PubMed/NCBI

25 

Cavalera M, Wang J and Frangogiannis NG: Obesity, metabolic dysfunction, and cardiac fibrosis: Pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res. 164:323–335. 2014. View Article : Google Scholar : PubMed/NCBI

26 

Fang Q, Wang J, Zhang Y, Wang L, Li W, Han J, Huang W, Liang G and Wang Y: Inhibition of myeloid differentiation factor-2 attenuates obesity-induced cardiomyopathy and fibrosis. Biochim Biophys Acta Mol Basis Dis. 1864:252–262. 2018. View Article : Google Scholar : PubMed/NCBI

27 

Querejeta R, López B, González A, Sánchez E, Larman M, Martinez Ubago JL and Díez J: Increased collagen type I synthesis in patients with heart failure of hypertensive origin: Relation to myocardial fibrosis. Circulation. 110:1263–1268. 2004. View Article : Google Scholar : PubMed/NCBI

28 

Ohashi K, Iwatani H, Kihara S, Nakagawa Y, Komura N, Fujita K, Maeda N, Nishida M, Katsube F, Shimomura I, et al: Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol. 27:1910–1917. 2007. View Article : Google Scholar : PubMed/NCBI

29 

Stokes MB, Holler S, Cui Y, Hudkins KL, Eitner F, Fogo A and Alpers CE: Expression of decorin, biglycan, and collagen type I in human renal fibrosing disease. Kidney Int. 57:487–498. 2000. View Article : Google Scholar : PubMed/NCBI

30 

Aleksandrova K, Mozaffarian D and Pischon T: Addressing the perfect storm: Biomarkers in obesity and pathophysiology of cardiometabolic risk. Clin Chem. 64:142–153. 2018. View Article : Google Scholar : PubMed/NCBI

31 

Jung HJ, Seu YB and Lee DG: Candicidal action of resveratrol isolated from grapes on human pathogenic yeast C. albicans. J Microbiol Biotechnol. 17:1324–1329. 2007.PubMed/NCBI

32 

Malhotra A, Bath S and Elbarbry F: An organ system approach to explore the antioxidative, anti-inflammatory, and cytoprotective actions of resveratrol. Oxid Med Cell Longev. 2015:8039712015. View Article : Google Scholar : PubMed/NCBI

33 

Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V and Della Ragione F: Resveratrol: From basic science to the clinic. Cell Cycle. 6:2495–2510. 2007. View Article : Google Scholar : PubMed/NCBI

34 

Gambini J, Inglés M, Olaso G, Lopez-Grueso R, Bonet-Costa V, Gimeno-Mallench L, Mas-Bargues C, Abdelaziz KM, Gomez-Cabrera MC, Vina J and Borras C: Properties of resveratrol: In vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid Med Cell Longev. 2015:8370422015. View Article : Google Scholar : PubMed/NCBI

35 

Modi S, Yaluri N and Kokkola T: Strigolactone GR24 and pinosylvin attenuate adipogenesis and inflammation of white adipocytes. Biochem Biophys Res Commun. 499:164–169. 2018. View Article : Google Scholar : PubMed/NCBI

36 

Aguirre L, Fernández-Quintela A, Arias N and Portillo MP: Resveratrol: Anti-obesity mechanisms of action. Molecules. 19:18632–18655. 2014. View Article : Google Scholar : PubMed/NCBI

37 

Baur JA and Sinclair DA: Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov. 5:4932006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 19 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, W., Chen, H., Sun, C., Wu, B., Bai, B., Liu, H. ... Zhang, Y. (2019). A novel resveratrol analog PA19 attenuates obesity‑induced cardiac and renal injury by inhibiting inflammation and inflammatory cell infiltration. Molecular Medicine Reports, 19, 4770-4778. https://doi.org/10.3892/mmr.2019.10157
MLA
Zhang, W., Chen, H., Sun, C., Wu, B., Bai, B., Liu, H., Shan, X., Liang, G., Zhang, Y."A novel resveratrol analog PA19 attenuates obesity‑induced cardiac and renal injury by inhibiting inflammation and inflammatory cell infiltration". Molecular Medicine Reports 19.6 (2019): 4770-4778.
Chicago
Zhang, W., Chen, H., Sun, C., Wu, B., Bai, B., Liu, H., Shan, X., Liang, G., Zhang, Y."A novel resveratrol analog PA19 attenuates obesity‑induced cardiac and renal injury by inhibiting inflammation and inflammatory cell infiltration". Molecular Medicine Reports 19, no. 6 (2019): 4770-4778. https://doi.org/10.3892/mmr.2019.10157